ImPrint Identifies Treatment for Patients With Breast Cancer ImPrint Identifies Treatment for Patients With Breast Cancer

Data from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news